PROTALIX BIOTHERAPEUTICS INC (PLX) Fundamental Analysis & Valuation

NYSEARCA:PLX • US74365A3095

Current stock price

2.295 USD
+0.02 (+0.66%)
Last:

This PLX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. PLX Profitability Analysis

1.1 Basic Checks

  • PLX had negative earnings in the past year.
  • In the past year PLX has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
  • PLX had negative operating cash flow in 4 of the past 5 years.
PLX Yearly Net Income VS EBIT VS OCF VS FCFPLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of PLX (6.56%) is better than 91.68% of its industry peers.
  • Looking at the Return On Equity, with a value of 10.20%, PLX belongs to the top of the industry, outperforming 92.46% of the companies in the same industry.
  • PLX has a better Return On Invested Capital (8.85%) than 92.46% of its industry peers.
Industry RankSector Rank
ROA 6.56%
ROE 10.2%
ROIC 8.85%
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLX Yearly ROA, ROE, ROICPLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • PLX has a better Profit Margin (8.72%) than 90.72% of its industry peers.
  • Looking at the Operating Margin, with a value of 10.30%, PLX belongs to the top of the industry, outperforming 90.52% of the companies in the same industry.
  • PLX's Gross Margin of 57.54% is fine compared to the rest of the industry. PLX outperforms 76.60% of its industry peers.
  • In the last couple of years the Gross Margin of PLX has declined.
Industry RankSector Rank
OM 10.3%
PM (TTM) 8.72%
GM 57.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
PLX Yearly Profit, Operating, Gross MarginsPLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PLX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PLX is destroying value.
  • PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLX Yearly Shares OutstandingPLX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLX Yearly Total Debt VS Total AssetsPLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • PLX has an Altman-Z score of -1.05. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.
  • PLX has a Altman-Z score (-1.05) which is in line with its industry peers.
  • PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.05
ROIC/WACC0.92
WACC9.57%
PLX Yearly LT Debt VS Equity VS FCFPLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

2.3 Liquidity

  • PLX has a Current Ratio of 3.03. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of PLX (3.03) is worse than 62.86% of its industry peers.
  • PLX has a Quick Ratio of 2.06. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.06, PLX is doing worse than 74.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 2.06
PLX Yearly Current Assets VS Current LiabilitesPLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. PLX Growth Analysis

3.1 Past

  • PLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -400.00%.
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-177.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-49.93%

3.2 Future

  • The Earnings Per Share is expected to grow by 70.23% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, PLX will show a quite strong growth in Revenue. The Revenue will grow by 11.99% on average per year.
EPS Next Y178.56%
EPS Next 2Y70.23%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.22%
Revenue Next 2Y11.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

PLX Yearly Revenue VS EstimatesPLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
PLX Yearly EPS VS EstimatesPLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. PLX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PLX. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 32.46, the valuation of PLX can be described as expensive.
  • Based on the Price/Forward Earnings ratio, PLX is valued cheaper than 91.68% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.68, PLX is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 32.46
PLX Price Earnings VS Forward Price EarningsPLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

  • 93.23% of the companies in the same industry are more expensive than PLX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.77
PLX Per share dataPLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

  • PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PLX's earnings are expected to grow with 70.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.23%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PLX Dividend Analysis

5.1 Amount

  • No dividends for PLX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PLX Fundamentals: All Metrics, Ratios and Statistics

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (4/10/2026, 3:27:51 PM)

2.295

+0.02 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-07
Inst Owners18.72%
Inst Owner Change0%
Ins Owners3.54%
Ins Owner Change0.8%
Market Cap184.56M
Revenue(TTM)N/A
Net Income(TTM)5.39M
Analysts80
Price Target11.22 (388.89%)
Short Float %6.06%
Short Ratio3.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-100%
Max EPS beat(2)-45.99%
EPS beat(4)1
Avg EPS beat(4)-95.93%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)1
Avg EPS beat(8)-123.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.69%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)14.45%
Revenue beat(4)1
Avg Revenue beat(4)-11.02%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)4
Avg Revenue beat(8)-1.08%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-85.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-120%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.46
P/S 2.98
P/FCF N/A
P/OCF N/A
P/B 3.49
P/tB 3.49
EV/EBITDA 17.77
EPS(TTM)-0.09
EYN/A
EPS(NY)0.07
Fwd EY3.08%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.77
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 6.56%
ROE 10.2%
ROCE 10.56%
ROIC 8.85%
ROICexc 17.24%
ROICexgc 17.24%
OM 10.3%
PM (TTM) 8.72%
GM 57.54%
FCFM N/A
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 117.56%
Cap/Sales 2.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.03
Quick Ratio 2.06
Altman-Z -1.05
F-Score6
WACC9.57%
ROIC/WACC0.92
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-177.78%
EPS Next Y178.56%
EPS Next 2Y70.23%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-49.93%
Revenue Next Year23.22%
Revenue Next 2Y11.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y171.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-35.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.35%
OCF growth 3YN/A
OCF growth 5YN/A

PROTALIX BIOTHERAPEUTICS INC / PLX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PLX.


Can you provide the valuation status for PROTALIX BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.


How profitable is PROTALIX BIOTHERAPEUTICS INC (PLX) stock?

PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.


Can you provide the financial health for PLX stock?

The financial health rating of PROTALIX BIOTHERAPEUTICS INC (PLX) is 6 / 10.


What is the earnings growth outlook for PROTALIX BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to grow by 178.56% in the next year.